STOCK TITAN
  1. Home
  2. News
  3. KYMR

Kymera Therapeutics Inc - KYMR STOCK NEWS

Welcome to our dedicated news page for Kymera Therapeutics (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kymera Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kymera Therapeutics's position in the market.

News
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
Rhea-AI Summary
Kymera Therapeutics, Inc. presents new preclinical data on KT-333, a First-in-Class STAT3 degrader, at AACR's poster session. Phase 1 dose escalation studies ongoing with more data expected in 2024. Founder Nello Mainolfi discusses drug discovery strategies. KT-333 shows strong anti-tumor activity by inducing a ternary complex between STAT3 and VHL E3 ligase. Phase 1 trials for KT-333 and KT-253 are in progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
-
News
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
Rhea-AI Summary
Kymera Therapeutics, Inc. announces preclinical data on KT-621 and KT-294, oral degraders targeting STAT6 and TYK2, with Phase 1 trials expected in 2024 and 2025 respectively. These degraders show potential in treating immune-mediated diseases, offering biologics-like activity with oral administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
clinical trial
-
News
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Kymera Therapeutics, Inc. (KYMR) will participate in several investor events to discuss their advancements in targeted protein degradation medicines. Webcasts of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
conferences
News
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) reported financial results for Q4 and full year 2023, with $745 million in cash as of January 9, 2024. The company is advancing its degrader portfolio with KT-474, KT-621, KT-294, KT-333, and KT-253 programs. Phase 2 data for KT-474 expected in 2025, Phase 1 for KT-621 in 2024, and Phase 1 for KT-294 in 2025. Positive clinical trial results for KT-474, KT-333, and KT-253. Kymera is well-capitalized and plans to continue its innovative pipeline expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
earnings
-
News
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) will release its fourth quarter and full year 2023 financial results on February 22, 2024. The company specializes in small molecule medicines using targeted protein degradation. Investors can join the conference call at 8:30 a.m. ET or access the webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
conferences earnings
-
News
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET. The company is a clinical-stage biopharmaceutical company focusing on small molecule medicines using targeted protein degradation (TPD). A live webcast of the fireside chat will be available on the company's website, with a replay option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
conferences
News
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs. The company has well-capitalized, with cash in excess of $745 million and expected runway into the first half of 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
none
-
News
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced the closing of its upsized underwritten public offering of $275 million of shares of its common stock, raising approximately $316.2 million. Morgan Stanley, J.P. Morgan, TD Cowen, and UBS Investment Bank acted as joint lead bookrunning managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
offering
-
News
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
Rhea-AI Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: KYMR), announced the pricing of its underwritten public offering of $275 million of shares of its common stock and pre-funded warrants to purchase shares of its common stock. The offering is expected to close on January 9, 2024, and the company intends to use the net proceeds for advancing its pipeline of preclinical and clinical degrader programs, working capital, and other general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
offering
News
Kymera Therapeutics Announces Proposed Public Offering
Rhea-AI Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: KYMR), has announced a public offering of $250.0 million of shares of its common stock and warrants to purchase shares. The company plans to use the net proceeds to advance its pipeline of preclinical and clinical degrader programs, address large patient populations, and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
offering
Stock KYMR logo
Kymera Therapeutics Inc

Nasdaq:KYMR

KYMR Rankings

#1819 Ranked by Market Cap
#4998 Ranked by Stock Gains
N/A Ranked by Dividends

KYMR Stock Data

2.17B
40.08M
1.38%
102.77%
14.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Watertown

About KYMR

kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.